© Copyright 2004 Frost & Sullivan. All Rights Reserved. World Psychiatric Therapeutics Markets Loss of Patent Protection Challenges Market Growth Pharmaceutical and Biotechnology Group “A lack of new drugs to counter the negative impact of patent expiration is expected to challenge growth in the psychiatric therapeutics market and expose it to competition from generic drugs.”

© Copyright 2004 Frost & Sullivan. All Rights Reserved. Industry Trends Research into Anticonvulsants: A total of 12 projects are underway. Much of the research into the development of new anticonvulsants is in the early stages of development (Phase II or earlier) Research into Antidepressants: There are at present 20 identified research and development projects underway in the area of depression. Eli Lilly’s Cymbalta approved by the FDA in 2004 is expected to reach blockbuster status. Research into Antipsychotics: Approximately 20 research and development projects are underway in an effort to discover the next big antipsychotic. Solvay Pharmaceutical’s Bifeprunox is a more advanced antipsychotic.To date the drug has shown none of the problematic side effects that accompany many of the existing products on the market.

© Copyright 2004 Frost & Sullivan. All Rights Reserved. Industry Trends (Cont’d) Negative Publicity: Both antipsychotics and antidepressants have come under increased scrutiny regarding their potential to cause harmful and in some cases deadly side effects. The American Diabetes Association issues an opinion singling out Zyprexa as the antipsychotic with the highest risk of diabetes. Researchers have determined that a link exists between the use of some antidepressants and suicidal tendencies in teenagers and children.

© Copyright 2004 Frost & Sullivan. All Rights Reserved. Key Features Frost & Sullivan Provides: Detailed insights into recent developments and trends Drivers, restraints, challenges, and strategic recommendations Analyst insights on ‘hot topics’ and emerging applications in the psychiatric therapeutics market Market sizing and competitive analysis Market forecasts and opportunity analysis End-user analysis within each report

© Copyright 2004 Frost & Sullivan. All Rights Reserved. What We Offer Coverage: Global Proven methodology encompassing extensive primary and secondary data and research Focused information and strategies that cover business and technology issues Credible data and analysis highlighting industry dynamics Winning strategies to help you create precise business plans

© Copyright 2004 Frost & Sullivan. All Rights Reserved. Who Will Benefit? Current Market Participants  Find out how you compare to the competition  Assess current and future drivers and restraints  Determine and exploit new market share opportunities New Entrants  Analyze challenges associated with the industry  Calculate time scales for strategy implementation  Position yourself to capitalize on the market’s unmet needs Investment Community  Analyze long-term strategies of psychiatric therapeutics companies  Determine which participants will outperform the competition  Assess attractiveness of investing in the psychiatric therapeutics market

© Copyright 2004 Frost & Sullivan. All Rights Reserved. What’s Included Anticonvulsants Markets Antidepressants Markets Antipsychotics Markets

© Copyright 2004 Frost & Sullivan. All Rights Reserved. Key Market Participants  Abbott Laboratories  Acadia Pharmaceuticals  Acorda Therapeutics  AstraZeneca  Bristol Myers Squibb  Cephalon  Dainippon  Eisai  Elan  Eli Lilly  Forest Laboratories  H. Lundbeck  Hoffman LaRoche  Icagen  Ivax Corp. .  Janssen Pharmaceuticals (Johnson and Johnson) Neuroscience Biosciences  Novartis  NPS Pharmaceuticals  Organon  Otsuka America  Pfizer  Repligen  Sanofi Synthelabo  Schwarz Pharmaceuticals  Solvay Pharmaceuticals  UCB Pharma  VistaGen  Wyeth  Xcel Pharmaceuticals

© Copyright 2004 Frost & Sullivan. All Rights Reserved.  Call toll free 877 GO FROST ( )  Fax toll free   Visit For More Information